1 June 2018
A diverse group of stakeholders learn about this exciting liquid biopsy technique and discuss its future applications.
Earlier in the year, PHG Foundation led a round-table event with representatives from the research, clinical, biotech/diagnostics, investment and insurance sectors to hear their feedback on recent developments and anticipated applications of these important technologies.
Circulating tumour (ct) DNA testing, also known as liquid biopsy, is a technique which analyses blood samples for small quantities of cell-free DNA that came from a patient's tumour.
Liquid biopsy is a less invasive medical procedure than a solid tumour biopsy, which has a risk of side-effects such as bleeding or tissue/organ damage. As with oher blood tests, liquid biopsy can be carried out more frequently throughout treatment, for example to monitor treatment response, or to detect the emergence of resistance to therapy.
Three speakers provided different perspectives to the current status of ctDNA technologies
From a research perspective…
The focus is to stratify patients to inform the most suitable care for their individual clinical needs. ctDNA allows the measurement of very specific genetic markers which are unique to the tumour concerned. However the real challenge affecting the use of liquid biopsies is the scarcity of ctDNA in the blood, which can constitute 10% of plasma cell-free DNA in advanced cancer patients, but significantly less in those with early-stage disease.
A significant application is to use ctDNA to monitor the status of patients, particularly as an indicator of relapse post-surgery and to direct additional treatment.
Early-stage diagnostics (for example for prostate cancer) have the potential to precede conventional biopsy techniques and may be integrated in the clinical pathway alongside imaging and pathology. However, a recent study shows only a 40% detection rate for early stage cancer detection, so we must be cautious to avoid over-stating current capabilities.
From an innovation perspective…
The challenge is taking the results of research and developing a clinically useful test based on ctDNA. Any test must inform clinical decision-making along the patient pathway – key applications are to inform:
However, progress is needed on improving and standardising technologies and decisions on how best to target testing are necessary. Significant investment will be required to fund this development and set up the studies necessary to test with patients.
From the NHS perspective…
ctDNA testing is already in use on a small-scale in the NHS, to test patients with non-small cell lung cancer who have failed solid tumour biopsy, to determine if they have mutations in a gene called EGFR. If so, the patient can receive a targeted drug. However not all eligible patients receive a test, so there is a challenge to be met in terms of supporting implementation of ctDNA testing and ensuring that it is available equitably. Key areas where action could be taken are:
The UK has a significant business advantage in the development of ctDNA technologies – given the right investment opportunities this may prove a vehicle to make a significant contribution to the British life science sector
Essential to their adoption is the education of clinicians to raise awareness of existing tests as well as guidance for the clinical application of these technologies - momentun is needed to establish guidelines.Health economic data is needed to prove the benefit of tests, even if they are yet be optimised.
Whilst drugs are approved for cancer treatment, companion diagnostics to help specify and target the treatment are missing. Also crucial will be a regulatory environment that keeps pace with the continuing development for ctDNA tests.
The implications of ctDNA testing are widespread and are having an impact beyond the healthcare and pharmaceutical sectors. Variability between different countries in how testing is used and regulated will have an impact on patients according to the rules of that country - there is a danger that some patients will receive suboptimal testing that hasn't been clinically proven.
Given an aging population, and the availability of improving technologies to detect cancer earlier, we will have to consider how to categorise cancer as a disease given that a) cancer is primarily a disease of aging and b) in some cases it can be treated for years as a chronic disease. This will have implications for the insurance sector in terms of how it defines disease, but more broadly these tests have the potential to make a significant contribution to cancer care, in terms of prescribing targeted drugs and monitoring patients during their treatment journey.